Gapping up
In reaction to strong earnings/guidance: PIR +26.5%, ARWR +9.5%, SAFM +5.3%, LLY +3.7% (reaffirms FY16 expectations, guides FY17, reaffirms financial expectations through the remainder of the decade).
Other news: CBIO +48.7% (Catalyst Biosciences entered into an agreement with Pfizer subsidiary Wyeth for the exclusive license to Wyeth's rights applying to CB813a & CB813d; co to make a $17.5 mln cash payment to Wyeth upon the achievement of milestones), BOSC +30.2% (receives $1.6 mln order for electronic components from an Indian electronics manufacturing co in the defense/aerospace industry; order is for delivery in 2017 and 2018), ACUR +11.0% (FDA has provided it with advice on the continued development of LTX-04; co intends to advance new formulations of LTX-04 tablets to a second pharmacokinetic study which is expected to start in late 1Q17), ONVO +5.7% (continued strength), NMM +4.9% (still checking for anything specific), MDLZ +4.9% (moved higher on rumor that Kraft Heinz (KHC) could be interested in acquiring co; subsequent reports have denied the rumor), WTW +1.9% (announces new subscription plan that includes a new Apple Watch Series 2 with the purchase of a Weight Watchers OnlinePlus membership), PPC +1.2% (up with SAFM).
Analyst actions: XLNX +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), COF +1.2% (upgraded to Neutral from Underperform at BofA/Merrill), MA +1.1% (upgraded to Buy from Neutral at BofA/Merrill).